Latest news with #MPOX
Associated Press
28-05-2025
- Business
- Associated Press
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the 'Company'), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Monday, June 16th, at 2:30pm at the BIO International Convention 2025 in Boston, MA. Event Information: Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing. Dr. Diwan will also be available for meetings in the BIO Partnering™ match-making platform during the Convention from June 16th through June 19th, 2025. NanoViricides' Current Antiviral Drugs Pipeline NanoViricides is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region. NV-387 is a revolutionary broad-spectrum drug candidate designed to mimic host-side features that the virus particle uses as the first landing site in order to mount a cellular infection. An estimated 90-95% of human pathogens utilize the same common landing feature that is mimicked by NV-387, giving the drug its extremely broad antiviral spectrum. NV-387 was found to be highly effective against the 'tripledemic' respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs. The virus cannot escape NV-387 even as it changes in the field, because the virus continues to use the sulfated proteoglycan features for attachment despite all changes. This is completely unlike existing vaccines, antibodies, and small chemical anti-viral modalities that are all readily defeated by viruses by relatively small changes, often in single viral proteins. The overall market size of NV-387 indications is estimated to be well in excess of $10 billion. NV-387 is expected to become an 'emperic therapy' for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections. NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection. This has tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection. In addition, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well. The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1. NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code-Specific Delivery Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery. Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work. Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack. ABOUT BIO INTERNATIONAL CONVENTION The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. In a time of remarkable discovery and progress, the biotechnology industry stands at the forefront of a revolution changing how we live, heal, and care. From pioneering treatments offering hope to millions, to sustainable agricultural innovations to feed a growing population, or environmental breakthroughs securing our future, biotech drives positive change faster than ever. This progress is not just a change but a promise for a brighter future. The world is ready. Whether you work at a public pharmaceutical company, biotech startup, academia, non-profit organization, or government agency; or you work as a researcher, business development professional or investor, BIO is where you'll make valuable connections and build relationships. Our proprietary BIO Partnering™ match-making platform-exclusive to the Premier Access registration package-allows you to find potential partners, schedule and accept meetings. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( ) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Contact: NanoViricides, Inc. [email protected] Public Relations Contact: [email protected] SOURCE: NanoViricides, Inc. press release
eNCA
23-05-2025
- Health
- eNCA
Nature of mpox necessitates rapid and accurate testing
PRETORIA - The South African Health Products Regulatory Authority has approved the country's first MPOX diagnostic test. It marks a significant step in supporting global access to MPOX testing. The nature of MPOX as in any other virus, requires accurate and reliable testing. The approval was made possible by reliance on prequalification and assessment by the World Health Organization.
Yahoo
27-03-2025
- Health
- Yahoo
Immunization funding pulled by Trump administration, Minneapolis Health Department says
The Brief The Minneapolis Health Department said federal immunization funding has been pulled back by the Trump administration. The funding was reportedly used to provide free vaccine education, clinics and immunization records for public schools. Three Minneapolis Health Department employees are also impacted and are currently being funded by other sources. MINNEAPOLIS (FOX 9) - Federal COVID-19 immunization funding has been pulled back by the Trump administration, the Minneapolis Health Department announced on Wednesday. The Minneapolis Health Department said the result is that vaccination clinics and immunization education "must cease immediately." What they're saying The funding was used to support the city's vaccination efforts, which included community education, free pediatric and adult clinics as well as updating the immunization records for Minneapolis Public School students. The city said the contacts it held with MHealth Fairview, Odam Medical Clinic and neighborhood HealthSource will cease immediately. The lack of funding also impacts three Minneapolis Health Department employees, who city officials say are currently being funded through other sources while other options are evaluated. Minneapolis Health Commissioner Damón Chaplin shared the following written statements: "The impact on our community is substantial. We are canceling five free vaccine clinics scheduled for April, and the future of our vaccine services in underserved communities is uncertain. Decisions at the federal level threaten public health now and in the future." The commissioner also said, "Decisions at the federal level are impacting lives and hurting employees dedicated to making Minneapolis a healthy place to live. Their work on our vaccine program has saved lives and prevented illnesses throughout the city. Eliminating federal support for these positions hurts our community and puts more burden on Minneapolis to deliver our mission to improve the health and well-being of every community member." By the numbers The Minneapolis Health Department said it partnered with community organizations to host 87 vaccine clinics in "underserved communities", which provided more than 800 COVID-19 vaccines, more than 700 flu shots, and more than 500 MPOX vaccines. The health department said it also provided 21 vaccine clinics, with 1,475 vaccinations administered and 501 patients served with 12 vaccines available to youth. The Minneapolis Health Department adds that as of Sept. 2024, only 70% of the city's 6-year-olds were up to date on their childhood vaccinations.
Zawya
15-03-2025
- Health
- Zawya
Annual Meeting of Data Managers for Epidemiological Surveillance in the Economic Community of West African States (ECOWAS) Region: Enhancing the "One Health" Approach
Hosted by the West African Health Organization (WAHO), in partnership with the Regional Animal Health Center (RAHC) and the Health Security Program for West and Central Africa (HeSP), the Annual Meeting of Data Managers for Epidemiological Surveillance based on the "One Health" approach, underscored the regional commitment to effective implementation of the approach, that comprehensively integrates human, animal, and environmental health dimensions to address health challenges. Since the introduction of the District Health Information System, version 2 (DHIS2) in 2014, WAHO has been instrumental in promoting data sharing related to epidemic-prone diseases across ECOWAS with the aim of improving the accessibility, availability, and dissemination of health information. Based on the lessons learned from the COVID-19 pandemic, the global alert level for monkeypox (MPOX), and ongoing screwworm outbreaks, the meeting focused on updating information on epidemiological surveillance in member countries, evaluating and enhancing data surveillance dashboards, and proposing strategies to strengthen coordination and data-sharing mechanisms among key stakeholders. The event gathered approximately 60 participants, including representatives from member countries, human and animal health data managers, and professionals responsible for epidemiological reporting, to assess the progress made, identify challenges, and strengthen collaboration in the use of epidemiological data. Mr. Raul KOUAME, Program Officer for Climate Change and Climate Services— ECOWAS Directorate of Environment and Natural Resources, emphasized the often-overlooked environmental impact on both physical and mental health, 'a comprehensive 'One Health' approach is essential to addressing the health challenges of our region,' he reiterated. Acting Director of the Regional Animal Health Center (RAHC), Dr. Hassane ADAKAL, discussed the role of domestic and wildlife species in the emergence of zoonotic diseases. Representing the WAHO Director General Dr. Melchior Athanase Joël Codjovi AÏSSI, Dr. Mamadou DIARRASSOUBA pointed out the importance of strengthening regional health security through the "One Health" approach. Data collected in 2024 revealed a significant increase in emerging infectious diseases in the ECOWAS region, with 67 new outbreaks identified—a 31.3% rise compared to 2023. The discussions, therefore, focused on the intergration of environmental and animal health indicators into regional platforms, harmonizing workflows among WAHO, the CRSCM, the RAHC, and member states, as well as strengthening the capacities of stakeholders involved in the "One Health" approach. The outcomes of this meeting, therefore, will guide the development of a robust regional report, supporting strategic planning and data integration into national and regional systems—representing a strategic opportunity to improve data quality, enhance early warning systems, and strengthen regional resilience to epidemics. Distributed by APO Group on behalf of The African Union – Interafrican Bureau for Animal Resources (AU-IBAR).
Associated Press
29-01-2025
- Business
- Associated Press
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
SHELTON, CT / ACCESS Newswire NNVC) (the 'Company'), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it is presenting today, January 29, at 11am at the MicroCap Conference 2025 in Atlantic City, NJ. Event Information: NanoViricides is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease. The Company has announced that it has engaged a CRO for conducting the Phase II clinical trials in the African Region. There is currently no treatment for hMPXV infection that causes the MPOX disease. Tecovirimat, (TPOXX®, SIGA) approved under 'Animal Rule' by the US FDA, failed in a clinical trial to demonstrate effectiveness for treating MPOX infection in a clinical trial. MPox Clade 1 and 1b infections have caused a continuing pandemic in the Africa that led to WHO declaring a Public Health Emergency of International Concern (PHEIC) in August 2024. Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Technologies available for licensing. The Phase II-ready drug NV-387 has demonstrated extremely broad antiviral spectrum of activity in animal models, which could prove to be as revolutionary for viral infections as penicillin was for bacterial infections. This broad spectrum is because NV-387 is designed to mimic a host-side feature that is used by over 90-95% of human pathogenic viruses when they cause infection. In light of the concerns regarding H5N1 Bird Flu and its potential spread, NV-387 is one of the most promising candidates that can respond to an Influenza pandemic. The Influenza virus would be unable to escape the NV-387 drug treatment because this drug mimics the feature on the host-side that all Influenza viruses continue to use for causing an infection, even as they evolve rapidly in the field. NV-387 has demonstrated activity substantially superior to each of oseltamivir (Tamiflu®), peramivir (Rapivab®), and baloxavir (Xofluza®) in lethal animal models of Influenza A lung viral infection. These approved drugs as well as vaccines and antibodies are readily escaped by the virus as it evolves in the field. NV-387 has also shown strong activity in lethal animal model studies for MPox and Smallpox treatment developments. There is no drug for the treatment of MPox infection at present. NV-387 has demonstrated cure of lethal RSV infection in animal model studies. There is no drug for the treatment of RSV infection at present, except for the last resort toxic drug ribavirin. NV-387 has demonstrated strong activity against coronavirus lethal animal models for SARS-CoV-2 infection (COVID-19). In addition, the Company has developed a platform that enables important non-oral drugs to be delivered as active oral drugs, which we believe is a sought after technology by Pharma companies. The overall market size of NV-387 indications is estimated to be well in excess of $10 billion. This year, registered attendees can view NanoViricides' presentation live, and also access a recorded version after the event. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week. Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks. The Microcap Conference is the largest independent microcap event in the U.S., featuring three days of one-on-one investor meetings, company presentations, expert discussions, and nonstop networking - all set against the vibrant backdrop of the Borgata in Atlantic City. Focused on high-quality companies, the conference provides unmatched access to our investor network, with participation fees and an event format that reflects our commitment to excellence. With an open admission policy, everyone is welcome. Plus, attendees can bring a guest to enjoy the entertainment and social activities alongside the conference experience. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. NanoViricides, Inc.
